Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)16.47bn
- Net income in MXN1.03bn
- Incorporated1996
- Employees1.78k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeALVARO OBREGON 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttps://www.genommalab.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ouro Fino Saude Animal Participacoes SA | 3.13bn | -165.76m | 3.85bn | 1.01k | -- | 1.70 | -- | 1.24 | -0.9295 | -0.9295 | 17.54 | 12.78 | 0.7186 | 1.92 | 3.34 | -- | -3.81 | 5.93 | -4.69 | 7.48 | 45.88 | 49.30 | -5.30 | 7.80 | 2.67 | 39.69 | 0.3852 | 16.83 | -9.40 | 9.87 | -138.25 | -- | -0.2692 | 14.07 |
| Blau Farmaceutica SA | 4.55bn | 828.57m | 6.30bn | 1.90k | 7.49 | 0.9286 | 6.54 | 1.37 | 1.40 | 1.40 | 7.67 | 11.26 | 0.4944 | 1.47 | 3.14 | 722,438.40 | 8.91 | 16.01 | 10.19 | 19.59 | 35.72 | 44.57 | 18.03 | 21.99 | 2.75 | -- | 0.2337 | 16.61 | -2.44 | 11.91 | -31.14 | 15.18 | 38.96 | -- |
| Biomm SA | 392.03m | -269.13m | 6.68bn | -- | -- | 11.83 | -- | 17.51 | -0.9737 | -0.9737 | 1.42 | 1.38 | 0.3153 | 2.23 | 5.05 | -- | -21.64 | -19.78 | -28.31 | -24.35 | 19.68 | 20.27 | -68.65 | -95.65 | 1.01 | -10.77 | 0.5554 | -- | 12.62 | 137.44 | 12.34 | -- | 40.29 | -- |
| Genomma Lab Internacional SAB de CV | 16.47bn | 1.03bn | 15.21bn | 1.78k | 13.64 | 1.47 | 11.43 | 0.9038 | 1.07 | 1.07 | 17.10 | 9.90 | 0.7791 | 3.01 | 3.63 | -- | 4.88 | 5.74 | 7.80 | 8.56 | 61.23 | 61.70 | 6.26 | 7.80 | 1.32 | 2.92 | 0.4011 | -- | -2.10 | 6.90 | -25.82 | -1.46 | -26.00 | -- |
| Hypera SA | 26.25bn | 5.47bn | 60.62bn | 9.00k | 11.14 | 1.58 | 9.66 | 2.30 | 2.58 | 2.58 | 12.40 | 18.18 | 0.328 | 1.33 | 3.06 | -- | 6.84 | 8.29 | 8.61 | 9.98 | 63.12 | 63.49 | 20.86 | 26.01 | 1.27 | -- | 0.4691 | 50.18 | 4.88 | 16.27 | -3.30 | 7.74 | 29.83 | 10.24 |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 29 Feb 2024 | 48.63m | 4.77% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 29.05m | 2.85% |
| MFS International (UK) Ltd.as of 31 Dec 2023 | 25.81m | 2.53% |
| Skagen AS (Investment Management)as of 31 Dec 2023 | 22.20m | 2.18% |
| BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 04 Apr 2024 | 20.72m | 2.03% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 20.28m | 1.99% |
| Wellington Management Co. LLPas of 29 Feb 2024 | 17.21m | 1.69% |
| Lemanik Asset Management SAas of 30 Jun 2023 | 15.86m | 1.56% |
| BlackRock M�xico Operadora SA de CV SOFIas of 31 Jan 2024 | 15.30m | 1.50% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 11.95m | 1.17% |
